Prognosis
J&J Shot Loses Antibody Protection Against Omicron in Study
- South Africa’s Moore says shot may still protect vs disease
- Moore gave presentation at an online African health conference
This article is for subscribers only.
Johnson & Johnson’s vaccine produced virtually no antibody protection against the omicron coronavirus variant in a laboratory experiment, underlining the new strain’s ability to get around one pillar of the body’s defenses.
The vaccine appears to provide some defense against omicron, perhaps via other means such as stimulation of immune cells, according to Penny Moore, a South African virologist. The findings are consistent with other studies that show a partial loss of potency against Covid-19 for a number of vaccines, with J&J’s antibody protection looking particularly weak in the lab test.